TY - JOUR
T1 - Metabolic tolerance to arginine
T2 - Implications for the safe use of arginine salt-aztreonam combination in the neonatal period
AU - Uauy, Ricardo
AU - Mize, Charles
AU - Argyle, Craig
AU - McCracken, George
N1 - Funding Information:
Arginine salts are being used increasingly as a way of improving drug solubility for parenteral use. Presently aztreonam, an injectable monocyclic ~-lactam antibiotic, is solubilized as an arginine salt. Arginine salt preparations have Supported by Bristol-Myers Squibb and by the University of Texas Southwestern Medical Center, General Clinical Research Center (grant No. M-01RR00633). Submitted for publication Oct. 23, 1990; accepted Feb. 4, 1991. Reprint requests: Ricardo Uauy, MD, PhD, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9063. 9/25/28478 the advantage of being stable, highly soluble, and sodium free, but the metabolic response of infants and neonates to a significant arginine load is unknown.
PY - 1991/6
Y1 - 1991/6
N2 - Two similar cohorts of low birth weight infants whose size was appropriate for gestational age randomly received either aztreonam-arginine plus ampicillin (n=15) or gentamicin plus ampicillin (n=15) for empiric treatment of neonatal sepsis. The regimens were infused together with glucose at >5 mg/kg per minute, and immediate (4 hours) and cumulative (3 days) effects were assessed. Serum arginine and insulin values rose immediately after administration of aztreonam (containing 0.15 mmol of arginine per kilogram), but there were no changes in the gentamicin-treated cohort; no differences occurred in either cohort in serum concentrations of glucose, ammonia, potassium, creatinine, and bilirubin. After 3 days of antibiotic therapy (n=13), the baseline serum arginine concentration was almost twice as high in the aztreonam group and showed a similar further rise and fall during the 4 hours after infusion; arginine urinary fractional excretion (normalized to creatinine clearance) decreased in the gentamicin group. The indirect bilirubin concentration rose more (p<0.001) in the aztreonam-treated infants (5.1 to 11.5 mg/dl (87 to 196 μmol/L)) than in the gentamicin-treated infants (5.5 to 8.1 mg/dl (94 to 138 μmol/L)). Thus a modest differential bilirubin response and modestly elevated baseline serum arginine level occurred after the 3-day low-arginine doses of this study; serum ammonia and glucose concentrations were not affected. Aztreonam-arginine in neonates was well tolerated metabolically, and we believe that it can be used safely in conjunction with attention to glucose and bilirubin metabolism.
AB - Two similar cohorts of low birth weight infants whose size was appropriate for gestational age randomly received either aztreonam-arginine plus ampicillin (n=15) or gentamicin plus ampicillin (n=15) for empiric treatment of neonatal sepsis. The regimens were infused together with glucose at >5 mg/kg per minute, and immediate (4 hours) and cumulative (3 days) effects were assessed. Serum arginine and insulin values rose immediately after administration of aztreonam (containing 0.15 mmol of arginine per kilogram), but there were no changes in the gentamicin-treated cohort; no differences occurred in either cohort in serum concentrations of glucose, ammonia, potassium, creatinine, and bilirubin. After 3 days of antibiotic therapy (n=13), the baseline serum arginine concentration was almost twice as high in the aztreonam group and showed a similar further rise and fall during the 4 hours after infusion; arginine urinary fractional excretion (normalized to creatinine clearance) decreased in the gentamicin group. The indirect bilirubin concentration rose more (p<0.001) in the aztreonam-treated infants (5.1 to 11.5 mg/dl (87 to 196 μmol/L)) than in the gentamicin-treated infants (5.5 to 8.1 mg/dl (94 to 138 μmol/L)). Thus a modest differential bilirubin response and modestly elevated baseline serum arginine level occurred after the 3-day low-arginine doses of this study; serum ammonia and glucose concentrations were not affected. Aztreonam-arginine in neonates was well tolerated metabolically, and we believe that it can be used safely in conjunction with attention to glucose and bilirubin metabolism.
UR - http://www.scopus.com/inward/record.url?scp=0025763748&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025763748&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(05)82219-X
DO - 10.1016/S0022-3476(05)82219-X
M3 - Article
C2 - 2040935
AN - SCOPUS:0025763748
SN - 0022-3476
VL - 118
SP - 965
EP - 970
JO - The Journal of pediatrics
JF - The Journal of pediatrics
IS - 6
ER -